Your session is about to expire
← Back to Search
RPT193 for Severe Asthma
Study Summary
This trial will test a potential asthma treatment in people with severe asthma who are already taking meds.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: RPT193 400 mg
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 3 null
- Follow Ups: You may be asked to continue sharing information regarding the trial for 3 Months after you stop receiving the treatment.
Frequently Asked Questions
Are individuals aged 65 and younger being considered for this clinical experiment?
"This trial is enrolling adults aged between 18 and 75."
Does this research endeavor currently accept participants?
"Affirmative. Clinicaltrials.gov displays that this clinical trial, initially posted on July 1st 2023 and updated lastly on July 4th 2023, is currently seeking out participants. Approximately 100 patients are required for the study from 4 different medical centres."
In what number of sites is this clinical investigation being overseen?
"The Allianz Research Institute CO in Aurora, Clinical Research Trials of Florida in Tampa and OK Clinical Research LLC in Edmond are just a few of the 4 sites actively involved with this trial."
How many individuals have signed up to partake in this investigation?
"RAPT Therapeutics, Inc. require 100 eligible participants to commence the trial from their two operational sites: Allianz Research Institute CO located in Aurora, Colorado and Clinical Research Trials of Florida situated in Tampa, Florida."
Do I meet the necessary criteria to participate in this experiment?
"This trial is actively seeking patients with asthma who are aged between 18 and 75. An approximate total of 100 people will be accepted into the study."
To what extent may taking RPT193 400 mg be hazardous to individuals?
"Despite lacking any evidence for efficacy, there is already some data that indicates RPT193 400 mg's safety - thus giving it a score of 2."
Share this study with friends
Copy Link
Messenger